Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
BNSLADPnXMFSLtn8
